JP6033783B2 - Ｐａｎ−ｈｅｒ抗体組成物 - Google Patents

Ｐａｎ−ｈｅｒ抗体組成物 Download PDF

Info

Publication number
JP6033783B2
JP6033783B2 JP2013535577A JP2013535577A JP6033783B2 JP 6033783 B2 JP6033783 B2 JP 6033783B2 JP 2013535577 A JP2013535577 A JP 2013535577A JP 2013535577 A JP2013535577 A JP 2013535577A JP 6033783 B2 JP6033783 B2 JP 6033783B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013535577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503188A (ja
JP2014503188A5 (enExample
Inventor
ミッケル・ワンダール・ペダーセン
イーダ・コー・クリステンセン
ヨハン・ラント
ヘレ・ヤコブセン
ミカエル・クラウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servier Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of JP2014503188A publication Critical patent/JP2014503188A/ja
Publication of JP2014503188A5 publication Critical patent/JP2014503188A5/ja
Application granted granted Critical
Publication of JP6033783B2 publication Critical patent/JP6033783B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013535577A 2010-11-01 2011-10-31 Ｐａｎ−ｈｅｒ抗体組成物 Expired - Fee Related JP6033783B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
US61/408,782 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
US61/531,407 2011-09-06
PCT/IB2011/054834 WO2012059857A2 (en) 2010-11-01 2011-10-31 Pan-her antibody composition

Publications (3)

Publication Number Publication Date
JP2014503188A JP2014503188A (ja) 2014-02-13
JP2014503188A5 JP2014503188A5 (enExample) 2014-12-18
JP6033783B2 true JP6033783B2 (ja) 2016-11-30

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013535577A Expired - Fee Related JP6033783B2 (ja) 2010-11-01 2011-10-31 Ｐａｎ−ｈｅｒ抗体組成物
JP2013535578A Expired - Fee Related JP6186277B2 (ja) 2010-11-01 2011-10-31 抗ｈｅｒ３抗体および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013535578A Expired - Fee Related JP6186277B2 (ja) 2010-11-01 2011-10-31 抗ｈｅｒ３抗体および組成物

Country Status (13)

Country Link
US (1) US9217039B2 (enExample)
EP (3) EP2635604B1 (enExample)
JP (2) JP6033783B2 (enExample)
KR (2) KR101773120B1 (enExample)
AU (2) AU2011324870B2 (enExample)
CA (2) CA2816520C (enExample)
DK (1) DK2635604T3 (enExample)
ES (2) ES2692379T3 (enExample)
IL (2) IL225953A0 (enExample)
MX (2) MX348637B (enExample)
PL (1) PL2635604T3 (enExample)
TW (1) TW201231066A (enExample)
WO (2) WO2012059857A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001927A (es) * 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012059857A2 (en) 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
EP2815765A1 (en) * 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
SI2726600T1 (sl) * 2011-07-01 2017-07-31 Amgen Inc. Sesalska celična kultura
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
WO2013148315A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
AU2018247916B2 (en) 2017-04-05 2025-04-24 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN112823167B (zh) 2018-09-07 2025-07-15 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
SG11202108737RA (en) * 2019-02-14 2021-09-29 Merus Nv Combinations of binding moieties that bind egfr, her2 and her3.
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
JP7774293B2 (ja) * 2019-07-24 2025-11-21 国立研究開発法人科学技術振興機構 抗体酵素の革新的製造技術
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
DK0896586T4 (en) 1996-03-27 2015-08-24 Genentech Inc ErbB3 antibodies.
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
EP1609803A4 (en) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODY AGAINST CD22 AND APPLICATIONS THEREOF
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
CA2587519A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
NZ579644A (en) * 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
BRPI0812091A2 (pt) 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante
WO2009065414A1 (en) 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
RU2010147652A (ru) 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
MX2011001927A (es) * 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
CN102265152A (zh) 2008-10-06 2011-11-30 西福根有限公司 鉴定和选择用于组合药品的药物候选物
KR20150036824A (ko) * 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
PT2417156E (pt) * 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
CN102378768A (zh) 2009-04-07 2012-03-14 罗氏格黎卡特股份公司 双特异性抗-ErbB-3/抗-c-Met抗体
JP2012525432A (ja) 2009-04-29 2012-10-22 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体
US9050375B2 (en) * 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
AU2010284018C1 (en) 2009-08-21 2015-10-15 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ErbB3 and uses thereof
CA2775573A1 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
TW201141519A (en) * 2010-03-04 2011-12-01 Symphogen As Anti-HER2 antibodies and compositions
KR101764453B1 (ko) * 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
ME02637B (me) * 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
WO2012059857A2 (en) 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition

Also Published As

Publication number Publication date
WO2012059858A1 (en) 2012-05-10
WO2012059857A2 (en) 2012-05-10
MX2013004899A (es) 2013-07-15
ES2616961T3 (es) 2017-06-14
IL225954B (en) 2018-05-31
KR20140026336A (ko) 2014-03-05
DK2635604T3 (en) 2017-02-27
EP2635605A1 (en) 2013-09-11
AU2011324870B2 (en) 2015-01-29
JP6186277B2 (ja) 2017-08-23
US9217039B2 (en) 2015-12-22
CA2816519C (en) 2019-01-15
JP2014503188A (ja) 2014-02-13
ES2692379T3 (es) 2018-12-03
IL225953A0 (en) 2013-07-31
TW201231066A (en) 2012-08-01
PL2635604T3 (pl) 2017-09-29
AU2011324871A1 (en) 2013-05-09
IL225954A0 (en) 2013-07-31
EP2635605B1 (en) 2018-07-25
CA2816519A1 (en) 2012-05-10
CA2816520A1 (en) 2012-05-10
MX347981B (es) 2017-05-22
EP2635605A4 (en) 2014-10-22
KR101862832B1 (ko) 2018-05-30
EP2635604B1 (en) 2016-11-30
US20130287684A1 (en) 2013-10-31
KR20140026337A (ko) 2014-03-05
WO2012059857A3 (en) 2012-07-19
KR101773120B1 (ko) 2017-08-30
EP3156421B1 (en) 2018-06-06
MX2013004897A (es) 2013-07-15
AU2011324871B2 (en) 2016-05-19
EP2635604A2 (en) 2013-09-11
EP3156421A1 (en) 2017-04-19
MX348637B (es) 2017-06-22
AU2011324870A1 (en) 2013-01-31
JP2014503189A (ja) 2014-02-13
CA2816520C (en) 2017-11-21

Similar Documents

Publication Publication Date Title
JP6186277B2 (ja) 抗ｈｅｒ３抗体および組成物
US10221246B2 (en) Pan-HER antibody composition
US8609095B2 (en) Anti-HER2 antibodies and compositions
JP6039428B2 (ja) 抗ｈｅｒ２抗体および組成物
JP6325527B2 (ja) ヒト化ｐａｎ−ｈｅｒ抗体組成物
JP2024029049A (ja) ＥＧＦＲ及びｃＭＥＴに結合する抗体
JP2016182135A (ja) 抗ｈｅｒ２抗体および組成物
BR112013010718A2 (pt) composição de anticorpo pan-her, composição farmacêutica, método para produção e uso da referida composição
BR112013010764A2 (pt) composição de anticorpos anti-her3, molécula de ligação biespecífica, molécula de ácido nucleico, vetor de expressão, linhagem celular policlonal, método para produção da referida composição, composição farmacêutica e uso da referida composição

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160830

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161026

R150 Certificate of patent or registration of utility model

Ref document number: 6033783

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees